Nuvation Bio

📍 New York, United States🗓 Founded 2018👥 59 employees💰 Last funded Oct 2020
Pharmaceutical Manufacturing🌐 nuvationbio.com
Website LinkedIn
Nuvation Bio (NYSE: NUVB) is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Nuvation Bio?
Nuvation Bio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Nuvation Bio last raise funding?
The most recent investment in Nuvation Bio recorded on gritt.io was in October 2020.
When was Nuvation Bio founded?
Nuvation Bio was founded in 2018.
What industry is Nuvation Bio in?
Nuvation Bio operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Nuvation Bio based?
Nuvation Bio is headquartered in New York, United States.